Third-generation EGFR TKIs (osimertinib, lazertinib, aumolertinib, furmonertinib, etc.), provide durable systemic disease control and CNS penetrance, and have become the cornerstone of frontline therapy for metastatic NSCLC with classical EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.